Neil Kumar, BridgeBio CEO (QED Therapeutics)

Eye­ing their first ap­proval, Bridge­Bio sends their first drug to the FDA and lands a speedy re­view

Over the last five years, Bridge­Bio has raised about $1 bil­lion, as­sem­bled over 20 dif­fer­ent com­pa­nies, ex­tend­ed net­works in­to Chi­na and Is­rael and scored part­ner­ships with a hand­ful of top aca­d­e­m­ic cen­ters. Now, for the first time, they’ll have a drug be­fore the FDA.

Bridge­Bio an­nounced to­day that the FDA has ac­cept­ed and hand­ed pri­or­i­ty re­view for fos­denopterin, an ex­per­i­men­tal med­i­cine for a rare, ir­re­versible neu­ro­log­i­cal con­di­tion that ap­pears in chil­dren and in­fants.  Picked up two years ago from Alex­ion, it was the lead mol­e­cule for Ori­gin Bio­sciences — a com­pa­ny they built specif­i­cal­ly for the sake of bring­ing it through late-stage tri­als.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.